Angiotensin II-mediated microvascular thrombosis.

Area of Science:

• Cardiovascular Physiology
• Renal Physiology
• Hemostasis and Thrombosis

Background:

• Hypertension is linked to increased thrombosis risk, suggesting interplay between the renin-angiotensin system and hemostasis.
• The specific microvascular sites and receptor subtypes involved in angiotensin II-mediated thrombosis remain incompletely understood.

Purpose of the Study:

• To investigate whether angiotensin II-induced thrombosis occurs in arterioles and/or venules.
• To assess the roles of angiotensin II type 1 (AT₁), type 2 (AT₂), and type 4 (AT₄) receptors, as well as endothelin 1 and bradykinin 1 and 2 receptors in angiotensin II-enhanced microvascular thrombosis.

Main Methods:

• Quantification of thrombus development in mouse cremaster microvessels following light/dye injury.
• Measurement of thrombus onset time and time to blood flow cessation.
• Utilized wild-type and AT₁ receptor-deficient mice, angiotensin II infusion, and specific receptor antagonists.

Main Results:

• Angiotensin II administration accelerated thrombosis in arterioles of both wild-type and AT₁ receptor-deficient mice.
• Platelet aggregation occurred at low angiotensin II concentrations, dependent on AT₁ receptors.
• Antagonism of AT₂ and AT₄ receptors, as well as endothelin 1 and bradykinin 1 receptors, significantly modulated angiotensin II-induced thrombosis.

Conclusions:

• Angiotensin II-induced hypertension is associated with enhanced arteriolar thrombosis.
• This thrombotic response involves a complex signaling cascade mediated by AT₂, AT₄, bradykinin 1, and endothelin 1 receptors.
• AT₁ receptor deficiency or antagonism did not abolish angiotensin II-enhanced thrombosis, suggesting alternative pathways are involved.